Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
Completed
Fudan University
Phase 1
2011-01-01
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular
endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent
inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted
to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the
pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and
multiple doses .
Phase I Study of Fruquintinib(HMPL-013) in Patients With Advanced Solid Tumors
Completed
Hutchison Medipharma Limited
Phase 1
2011-01-01
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular
endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent
inhibitory effects on multiple human tumor xenografts. This first-in-human study is conducted
to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the
pharmacokinetics , safety and preliminary anti-tumor activity of HMPL-013 at single doses and
multiple doses .
Fruquintinib is a novel oral small molecule compound discovered and developed by Hutchison
MediPharma that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1,
2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor
xenografts.Based on first-in-human study, both 4mg QD and 5mg 3wks on/1wk off are safety and
efficacy, this phase Ib study is to evaluable the safety, tolerability and efficacy of these
2 regimens with mCRC failed 2nd therapy or more and to determine the recommended dose and
regimen in phase II/III study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
